ADXS vs. AEZS, ITRM, BIOR, MEIP, PIRS, HCWB, COCP, SPRB, IPA, and NERV
Should you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Aeterna Zentaris (AEZS), Iterum Therapeutics (ITRM), Biora Therapeutics (BIOR), MEI Pharma (MEIP), Pieris Pharmaceuticals (PIRS), HCW Biologics (HCWB), Cocrystal Pharma (COCP), Spruce Biosciences (SPRB), ImmunoPrecise Antibodies (IPA), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical preparations" industry.
Aeterna Zentaris (NASDAQ:AEZS) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.
0.7% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 0.1% of Aeterna Zentaris shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aeterna Zentaris has higher revenue and earnings than Ayala Pharmaceuticals. Aeterna Zentaris is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aeterna Zentaris received 419 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 61.53% of users gave Aeterna Zentaris an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
Aeterna Zentaris presently has a consensus target price of $60.00, indicating a potential upside of 1,021.50%. Given Ayala Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aeterna Zentaris is more favorable than Ayala Pharmaceuticals.
In the previous week, Aeterna Zentaris had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Aeterna Zentaris and 1 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.72 beat Aeterna Zentaris' score of 0.00 indicating that Aeterna Zentaris is being referred to more favorably in the media.
Ayala Pharmaceuticals has a net margin of 0.00% compared to Ayala Pharmaceuticals' net margin of -760.32%. Aeterna Zentaris' return on equity of 0.00% beat Ayala Pharmaceuticals' return on equity.
Aeterna Zentaris has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.
Summary
Aeterna Zentaris beats Ayala Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Ayala Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ayala Pharmaceuticals Competitors List
Related Companies and Tools
